연구성과로 돌아가기
2024 연구자 정보 (193 / 1079)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| Author Name | 제1저자 여부 | 교신저자 여부 | Address | ResearcherID | ORCID | Paper Title | WoS Edition | 최상위 JCR(%) | WoS Category | Related Email |
|---|---|---|---|---|---|---|---|---|---|---|
|
Schreiber, Martin (Schreiber, M) |
DaVita Integrated Kidney Care, Denver, CO USA |
|
|
[JCR상위 6.4] Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus | SCIE | 6.4 | UROLOGY & NEPHROLOGY | KarthikK.Tennankore@nshealth.ca; | ||
|
Seong, Eun Young (Seong, EY) |
Pusan Natl Univ Hosp, Dept Internal Med, Div Nephrol, Busan, South Korea |
|
|
[JCR상위 6.4] Bioimpedance-Guided Fluid Removal in Continuous KRT The VENUS Randomized Clinical Trial | SCIE | 6.4 | UROLOGY & NEPHROLOGY | sejoong@snubh.org; | ||
|
Shen, Jenny (Shen, J) |
Harbor UCLA Med Ctr, Lundquist Inst, Torrance, CA USA |
|
|
[JCR상위 6.4] Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus | SCIE | 6.4 | UROLOGY & NEPHROLOGY | KarthikK.Tennankore@nshealth.ca; | ||
|
Shin, Junghee J. (Shin, JJ) |
Yale Univ, Sch Med, Dept Internal Med, Sect Rheumatol Allergy & Immunol, New Haven, CT 06520 USA |
|
|
[JCR상위 6.4] IL-1 receptor 1 signaling shapes the development of viral antigen-specific fi c CD4+ | SCIE | 6.4 | MEDICINE, RESEARCH & EXPERIMENTAL | insoo.kang@yale.edu; | ||
|
Shin, Min Sun (Shin, MS) |
Yale Univ, Sch Med, Dept Internal Med, Sect Rheumatol Allergy & Immunol, New Haven, CT 06520 USA |
|
0000-0003-2516-9251 Shin, Min Sun |
[JCR상위 6.4] IL-1 receptor 1 signaling shapes the development of viral antigen-specific fi c CD4+ | SCIE | 6.4 | MEDICINE, RESEARCH & EXPERIMENTAL | insoo.kang@yale.edu; | ||
|
Suttichaimongkol, T. (Suttichaimongkol, T) |
Khon Kaen Univ, Dept Med, Div Gastroenterol & Hepatol, Fac Med, Khon Kaen, Thailand |
|
|
[JCR상위 6.4] mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | SCIE | 6.4 | ONCOLOGY;RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | |||
|
Tak, W. Y. (Tak, WY) |
Kyungpook Natl Univ, Sch Med, Dept Internal Med, Daegu, South Korea |
|
|
[JCR상위 6.4] mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | SCIE | 6.4 | ONCOLOGY;RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | |||
|
Tennankore, Karthik K. (Tennankore, KK) |
제1저자 | 교신저자 | Dalhousie Univ, Dept Med, Halifax, NS, Canada |
K-6600-2019 Tennankore, Karthik |
0000-0002-7919-6709 Tennankore, Karthik |
[JCR상위 6.4] Prevalence and Outcomes of Chronic Kidney Disease-Associated Pruritus | SCIE | 6.4 | UROLOGY & NEPHROLOGY | KarthikK.Tennankore@nshealth.ca; |
|
Yoon, J. H. (Yoon, JH) |
Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea Seoul Natl Univ, Coll Med, Liver Res Inst, Seoul, South Korea |
ABA-5127-2021 Yoon, Jeong Hee |
|
[JCR상위 6.4] mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | SCIE | 6.4 | ONCOLOGY;RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | |||
|
Zhen, Xing (Zhen, X) |
제1저자 |
Korea Res Inst Biosci & Biotechnol KRIBB, Natl Primate Res Ctr NPRC, Cheongju 28116, South Korea Kyungpook Natl Univ, Grad Sch, Dept Nanosci & Nanotechnol, Daegu 41566, South Korea |
|
|
[JCR상위 6.4] Homology-independent targeted insertion-mediated derivation of M1-biased macrophages harbouring Megf10 and CD31; 1; from human pluripotent stem cells | SCIE | 6.4 | MEDICINE, RESEARCH & EXPERIMENTAL | jonglee@kribb.re.kr;zhenxing93@kribb.re.kr;jieun622@kribb.re.kr;byung127@kribb.re.kr;kanjon@kribb.re.kr;brightnessd@kribb.re.kr;shhong@kangwon.ac.kr;lee1@knu.ac.kr; | |
|
Zotkiewicz, M. (Zotkiewicz, M) |
AstraZeneca, Late Oncol Stat, Oncol Biometr, Warsaw, Poland |
|
|
[JCR상위 6.4] mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma | SCIE | 6.4 | ONCOLOGY;RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | |||
|
Ahn, Kyu Jeung (Ahn, KJ) |
Kyung Hee Univ, Kyung Hee Univ Hosp Gangdong, Coll Med, Dept Endocrinol & Metab, Seoul, South Korea |
|
|
[JCR상위 6.5] Efficacy and Safety of Metformin and Atorvastatin Combination Therapy vs. Monotherapy with Either Drug in Type 2 Diabetes Mellitus and Dyslipidemia Patients (ATOMIC): Double-Blinded Randomized Controlled Trial | SCIE | 6.5 | ENDOCRINOLOGY & METABOLISM | leemk4132@gmail.com; | ||
|
Bae, Jaehyun (Bae, J) |
제1저자 |
|
|
[JCR상위 6.5] Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association | SCIE | 6.5 | ENDOCRINOLOGY & METABOLISM | bwanlee@yuhs.ac; | ||
|
Bae, Ji-Cheol (Bae, JC) |
Sungkyunkwan Univ, Sch Med, Samsung Changwon Hosp, Div Endocrinol & Metab,Dept Internal Med, Gyeongsangnam Do, South Korea |
|
|
[JCR상위 6.5] Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association | SCIE | 6.5 | ENDOCRINOLOGY & METABOLISM | bwanlee@yuhs.ac; | ||
|
Cha, Bong-Soo (Cha, BS) |
Yonsei Univ, Dept Internal Med, Div Endocrinol & Metab, Coll Med, 50-1 Yonsei Ro, Seoul 03722, South Korea Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea |
|
0000-0003-0542-2854 Cha, Bong-Soo |
[JCR상위 6.5] Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association [JCR상위 27.0] Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate- Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE) |
SCIE | 6.5 | ENDOCRINOLOGY & METABOLISM |
bwanlee@yuhs.ac; kcwon@med.yu.ac.kr;yschung@ajou.ac.kr;k50367@korea.ac.kr; |
페이지 이동: